Rapid blood protein response and remission in AL amyloidosis
Treatments studied
Part of Cancer, Hormones & metabolism, Immune system & allergy clinical trials.
This trial is for people with AL amyloidosis who are being treated with daratumumab, bortezomib, and dexamethasone. It looks at how quickly a certain blood protein (called dFLC) drops after treatment starts and whether that predicts a complete remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with AL amyloidosis.
- Your treatment includes daratumumab, bortezomib, and dexamethasone.
- Your dFLC level (a measure of abnormal protein in the blood) is 50 mg/L or higher.
- You do not have active multiple myeloma or a related blood cancer.
- You do not have an advanced or spreading tumor, a severe infection not well controlled, a severe autoimmune disease, active hepatitis B or C, HIV, or syphilis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new combination of medicines (daratumumab, bortezomib, and dexamethasone) as the first treatment for people with a specific type of amyloidosis (AL amyloidosis). It aims to see if this combination works better than standard care.
This trial tests a combination of three drugs—bortezomib, pomalidomide, and dexamethasone—to see how well they work for people with AL amyloidosis, a condition where abnormal proteins build up in organs. You may join if you are newly diagnosed or have had prior treatment and your organs are affected.
This trial tests a new drug combination for people with a specific type of AL amyloidosis (light chain amyloidosis) that has a genetic marker called t(11;14). The treatment includes Sonrotoclax (a targeted therapy) plus steroids, and possibly another drug called daratumumab, to see if it can help control the disease.
This study looks for 'minimal residual disease' (tiny traces of amyloid after treatment) in people with AL amyloidosis who have had a stem cell transplant. It helps doctors understand if more treatment is needed.
This trial tests a new drug (SCTC21C) combined with three standard chemotherapy medicines for people who have just been diagnosed with AL amyloidosis. The goal is to see if adding the new drug helps reduce the abnormal protein deposits better than the standard treatment alone.
This trial tests an experimental drug, teclistamab, for people with a type of amyloidosis (AL) that has not improved with standard treatments. It aims to see if teclistamab can help when other treatments have not worked.
Hear when a new Systemic AL Amyloidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.